252662-47-8
Chemical Structure
Toralizumab
Synonym(s): IDEC-131; Anti-Human CD40 ligand Recombinant Antibody
- CAS No.: 252662-47-8
- Formula:N/A
- Molecular Weight:(145.66 kDa)
IUPAC Name: tert-butyl 4-benzyl-2-(chloromethyl)-5-oxopiperazine-1-carboxylate
SMILES: [Toralizumab]
Biological Activity: Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Toralizumab | 99.57% | Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Camilo E Fadul, et al. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 15;8(6):e1096. [Content Brief]
- [2]. Kenneth C Kalunian, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec;46(12):3251-8. [Content Brief]
- [3]. Murphy, G., & Isenberg, D. A. (2019). New therapies for systemic lupus erythematosus - past imperfect, future tense. Nature reviews. Rheumatology, 15(7), 403-412. [Content Brief]
Keywords
